Summit-07: A Randomized Trial of Nktr-181, a New Molecular Entity, Full Mu-Opioid Receptor Agonist for Chronic Low-Back Pain

NKTR-181, a new molecular entity, mu-opioid receptor agonist with an inherently slow rate of central nervous system (CNS) entry, was designed to provide analgesia while reducing abuse potential. Full story.